Skip Nav Destination
Issues
1 April 2008
-
Cover Image
Cover Image
This pericardial metastasis from an infiltrating ductal carcinoma primary shows predominantly nested morphology, consistent with ductal differentiation. However, in the lower portion of the field, sheets and cords of signet ring cells are present, indicating lobular differentiation. Immunohistochemical labeling for E-cadherin was diminished in the lobular areas. Other distant metastases in this case were exclusively lobular and lacked E-cadherin expression. For further details, please see the article by Wu and associates on page 1938 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
The Clinical Connection
Molecular Pathways
Review
Human Cancer Biology
Heterogeneity of Breast Cancer Metastases: Comparison of Therapeutic Target Expression and Promoter Methylation Between Primary Tumors and Their Multifocal Metastases
Julie M. Wu; Mary Jo Fackler; Marc K. Halushka; Diana W. Molavi; M. Evangeline Taylor; Wei Wen Teo; Constance Griffin; John Fetting; Nancy E. Davidson; Angelo M. De Marzo; Jessica L. Hicks; Dhananjay Chitale; Marc Ladanyi; Saraswati Sukumar; Pedram Argani
Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma In situ of the Breast
Anne Vincent-Salomon; Carlo Lucchesi; Nadège Gruel; Virginie Raynal; Gaëlle Pierron; Rémi Goudefroye; Fabien Reyal; François Radvanyi; Rémy Salmon; Jean-Paul Thiery; Xavier Sastre-Garau; Brigitte Sigal-Zafrani; Alain Fourquet; Olivier Delattre; for the breast cancer study group of the Institut Curie
Imaging, Diagnosis, Prognosis
Early Metabolic Response Evaluation by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Allows In vivo Testing of Chemosensitivity in Gastric Cancer: Long-term Results of a Prospective Study
Katja Ott; Ken Herrmann; Florian Lordick; Hinrich Wieder; Wolfgang A. Weber; Karen Becker; Andreas K. Buck; Martin Dobritz; Ulrich Fink; Kurt Ulm; Tibor Schuster; Markus Schwaiger; Jörg-Rüdiger Siewert; Bernd J. Krause
Human Leukocyte Antigen Class I, MHC Class I Chain-Related Molecule A, and CD8+/Regulatory T-Cell Ratio: Which Variable Determines Survival of Cervical Cancer Patients?
Ekaterina S. Jordanova; Arko Gorter; Ouissam Ayachi; Frans Prins; Lindy G. Durrant; Gemma G. Kenter; Sjoerd H. van der Burg; Gert Jan Fleuren
Glioma Proliferation as Assessed by 3‘-Fluoro-3’-Deoxy-l-Thymidine Positron Emission Tomography in Patients with Newly Diagnosed High-Grade Glioma
Roland Ullrich; Heiko Backes; Hongfeng Li; Lutz Kracht; Hrvoje Miletic; Kristina Kesper; Bernd Neumaier; Wolf-Dieter Heiss; Klaus Wienhard; Andreas H. Jacobs
Gene Expression–Based Recurrence Prediction of Hepatitis B Virus–Related Human Hepatocellular Carcinoma
Hyun Goo Woo; Eun Sung Park; Jae Hee Cheon; Ju Han Kim; Ju-Seog Lee; Bum Joon Park; Won Kim; Su Cheol Park; Young Jin Chung; Byeong Gwan Kim; Jung-Hwan Yoon; Hyo-Suk Lee; Chung Yong Kim; Nam-Joon Yi; Kyung-Suk Suh; Kuhn Uk Lee; In-Sun Chu; Tania Roskams; Snorri S. Thorgeirsson; Yoon Jun Kim
Cancer Therapy: Clinical
A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
Debashis Sarker; Rhoda Molife; T.R. Jeffrey Evans; Maryon Hardie; Cheryl Marriott; Priska Butzberger-Zimmerli; Rosemary Morrison; Judith A. Fox; Carla Heise; Sharianne Louie; Natasha Aziz; Felix Garzon; Glenn Michelson; Ian R. Judson; Dalal Jadayel; Edgar Braendle; Johann S. de Bono
Anemia Is a Significant Prognostic Factor in Local Relapse-Free Survival of Premenopausal Primary Breast Cancer Patients Receiving Adjuvant Cyclophosphamide/Methotrexate/5-Fluorouracil Chemotherapy
Peter Dubsky; Paul Sevelda; Raimund Jakesz; Hubert Hausmaninger; Hellmut Samonigg; Michael Seifert; Ursula Denison; Brigitte Mlineritsch; Günther Steger; Werner Kwasny; Herbert Stöger; Rupert Bartsch; Michael Stierer; Susanne Taucher; Michael Fridrik; Walter Schippinger; Richard Greil; Richard Pötter; Michael Gnant; for the Austrian Breast and Colorectal Cancer Study Group
The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal Hemorrhage in Advanced Non–Small Cell Lung Cancer Patients Treated with Erlotinib and Celecoxib
Mary J. Fidler; Athanassios Argiris; Jyoti D. Patel; David H. Johnson; Alan Sandler; Victoria M. Villaflor; John Coon, IV; Lela Buckingham; Kelly Kaiser; Sanjib Basu; Philip Bonomi
Pilot Randomized Phase II Study of Celecoxib in Oral Premalignant Lesions
Vassiliki A. Papadimitrakopoulou; William N. William, Jr.; Andrew J. Dannenberg; Scott M. Lippman; J. Jack Lee; Frank G. Ondrey; Douglas E. Peterson; Lei Feng; Anthea Atwell; Adel K. El-Naggar; Cherie-Ann Nathan; Joseph I. Helman; Baoheng Du; Bevan Yueh; Jay O. Boyle
Cancer Therapy: Preclinical
Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH2): Observation of a U-Shaped Dose-Response Curve in Several Preclinical Models of Angiogenesis and Tumor Growth
Fernando Doñate; Graham C. Parry; Yuval Shaked; Harvey Hensley; Xiaojun Guan; Ivy Beck; Ziva Tel-Tsur; Marian L. Plunkett; Mari Manuia; David E. Shaw; Robert S. Kerbel; Andrew P. Mazar
DTS-108, A Novel Peptidic Prodrug of SN38: In vivo Efficacy and Toxicokinetic Studies
Florence Meyer-Losic; Céline Nicolazzi; Jérôme Quinonero; Fabien Ribes; Matthieu Michel; Vincent Dubois; Catherine de Coupade; Matthieu Boukaissi; Anne-Sophie Chéné; Isabelle Tranchant; Valérie Arranz; Imane Zoubaa; Jean-Sébastien Fruchart; Denis Ravel; Jonathan Kearsey
An In vivo Model of Met-Driven Lymphoma as a Tool to Explore the Therapeutic Potential of Met Inhibitors
Paolo Accornero; Giuseppe Lattanzio; Tony Mangano; Roberto Chiarle; Riccardo Taulli; Francesca Bersani; Paolo E. Forni; Silvia Miretti; Claudio Scuoppo; Walter Dastrù; James G. Christensen; Tiziana Crepaldi; Carola Ponzetto
Cancer Prevention and Susceptibility
Letters to the Editor
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds